Search Results

You are looking at 211 - 220 of 955 items for :

  • "community" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo

) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1

Full access

Joyce LaMori, Kai Zu, Kristina L. Greenwood, Besa Smith, Tyler Smith, and Alaina Lee

’ psychosocial problems may be targets to prevent unplanned acute care utilization (“readmission”). Methods: The study included 933 unique adult patients admitted to four acute care inpatient facilities within a non-profit community based healthcare system in

Full access

Adam C. Powell, Christopher T Lugo, Jeremy T Pickerell, James W Long, Amin J Mirhadi, and Bryan A Loy

significantly less likely to deem orders appropriate for older patients (OR: 0.97; CI: 0.96-0.98), urban patients (OR: 0.75; CI: 0.61-0.90), and patients with a history of breast MRI (OR: 0.66; CI: 0.54-0.81). Orders for patients from communities with median

Full access

Robin M. Lally, Elizabeth Reed, and Roksana Zak

an expert medical oncologist known in the community. Ease of access was supported by hosting pathways on a newly developed website along with expert-developed, NCCN guideline supported, educational webinars. Transparency was

Full access

Ran Jin, Neil Accortt, Darcie Sandschafer, Tatiana Lawrence, and Reshma Mahtani

geographically diverse, and includes more than 2.2 million US cancer patients (primarily treated in a community setting) from >280 cancer clinics. Results: First use of trastuzumab-anns was in early stage BC (eBC) and occurred 4 days after product launch. 2

Full access

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang, and Zin Myint

was 154 days. Majority (60%) were treated at academic and 24% at comprehensive community. Only 28% achieved complete pathological complete response rate (Tis or T0). On univariate analysis patients receiving surgery within 30 weeks of diagnosis had

Full access

happens in the community. A number of factors influence the administration of chemotherapy. For example, younger age and having private insurance are associated with higher rates. 2 The very low rates of crossover to the maintenance therapy in the

Full access

Prakash Manoharan, Ahmed Salem, Hitesh Mistry, and Corinne Faivre-Finn

controlled trial is required to settle this debate. However, in our view, there is little interest in conducting such a trial among the oncology and imaging communities. We encourage continued debate and reflection of published data regarding the impact of

Full access


thoughtful commentaries and editorials, often from Dr. Winn and the panel chairs who serve as issue editors. This themed model served JNCCN well, and the journal enjoyed early success in the oncology community as measured by independent readership surveys

Full access

Robert C. Young

guidelines would benefit both the NCCN Member Institutions and the oncology community in general. However, once the decision to proceed was made, the organization faced 2 substantial challenges: traditional support from the pharmaceutical industry was